Figure 7: Correlation between tumour TNNC1 and stromal MFAP5 expression in human HGSC samples revealed the clinical relevance of TNNC1 to ovarian cancer patient survival.

(a) Abrogation of MFAP5-induced increase in TNNC1 mRNA expression in A224, ALST and OVCA432 cells after pretreatment with the cell-permeant calcium chelator BAPTA/AM, a CBP/CREB inhibitor or a c-Jun inhibitor (mean±s.d. of three independent experiments; two-tailed Student’s t-test). (b) Immunolocalization of TNNC1 and MFAP5 in advanced-stage HGSC tumour sections demonstrating a positive correlation between high stromal MFAP5 and high tumour TNNC1 expression. S, stroma; T, tumour. Bar=100 μm. (c) Positive correlation between stromal MFAP5 expression and tumour TNNC1 expression in HGSC tumours (N=107; r=0.515; P<0.001; Spearman’s Correlation). (d) Kaplan–Meier analysis of the clinical significance of tumour TNNC1 expression with 107 FFPE tumour samples obtained from HGSC patients. Low tumour TNNC1 expression was significantly correlated with improved overall patient survival (N=107; P=0.018; log-rank test).